Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05882279 · ADVERSE EVENTS

Adverse events

A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan · Source last updated 2024-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected/assessed in this study
Other-event reporting threshold
0%

This was a web-based multiple choice questionnaire survey of pharmacists which did not include safety information as adverse events were not planned to be collected in this study. Data '0' for total number of participants at risk/affected for sections all-cause mortality, serious adverse events, and other (not including serious adverse events) signifies that adverse events were not collected and assessed in this study.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Pharmacists in Hospitals Prescribing NINLARO

Pharmacists included in Nikkei Medical Online Panel, active in clinical practice, and with valid contact details who belonged to hospitals and have instructed the dosing of NINLARO (ixazomib) in combination with lenalidomide and dexamethasone (IRD therapy) to patients were selected to participate in the survey.

0 / 00 / 00 / 0

Group identifiers: EG000: Pharmacists in Hospitals Prescribing NINLARO

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      This was a web-based multiple choice questionnaire survey of pharmacists which did not include safety information as adverse events were not planned to be collected in this study. Data '0' for total number of participants at risk/affected for sections all-cause mortality, serious adverse events, and other (not including serious adverse events) signifies that adverse events were not collected and assessed in this study.
      event Groups
      1. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Pharmacists included in Nikkei Medical Online Panel, active in clinical practice, and with valid contact details who belonged to hospitals and have instructed the dosing of NINLARO (ixazomib) in combination with lenalidomide and dexamethasone (IRD therapy) to patients were selected to participate in the survey.
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Pharmacists in Hospitals Prescribing NINLARO
      frequency Threshold
      0
      time Frame
      All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected/assessed in this study

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice